Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients With Severe Haemophilia A: Results of an Interventional, Post-Marketing Study.

IF 3 2区医学 Q2 HEMATOLOGY

Haemophilia Pub Date : 2025-08-21 DOI:10.1111/hae.70099

Pål André Holme, Lone Hvitfeldt Poulsen, Claudia Tueckmantel, Monika Maas Enriquez, María Teresa Alvarez Román, Raimondo De Cristofaro

引用次数: 0

Abstract

: This is a plain language summary of the results of a trial of damoctocog alfa pegol (BAY 94-9027, Jivi).

查看原文本刊更多论文

Damoctocog Alfa Pegol预防严重血友病A患者的安全性和有效性：一项介入性上市后研究的结果

这是damoctocog alfa pegol试验结果的简单语言总结（BAY 94-9027, Jivi）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haemophilia 医学-血液学

CiteScore

6.50

自引率

28.20%

发文量

226

审稿时长

3-6 weeks

期刊介绍： Haemophilia is an international journal dedicated to the exchange of information regarding the comprehensive care of haemophilia. The Journal contains review articles, original scientific papers and case reports related to haemophilia care, with frequent supplements. Subjects covered include: clotting factor deficiencies, both inherited and acquired: haemophilia A, B, von Willebrand''s disease, deficiencies of factor V, VII, X and XI replacement therapy for clotting factor deficiencies component therapy in the developing world transfusion transmitted disease haemophilia care and paediatrics, orthopaedics, gynaecology and obstetrics nursing laboratory diagnosis carrier detection psycho-social concerns economic issues audit inherited platelet disorders.